Upstream Bio, Inc.

UPB Nasdaq CIK: 0002022626

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 890 WINTER STREET, SUITE 200, WALTHAM, MA, 02451
Mailing Address 890 WINTER STREET, SUITE 200, WALTHAM, MA, 02451
Phone 781-208-2466
Fiscal Year End 1231
EIN 000000000

Financial Overview

FY2025

$469.85M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 26, 2026 View on SEC
424B5 Prospectus supplement March 26, 2026 View on SEC
10-K Annual financial report March 26, 2026 View on SEC
8-K Current report of material events March 26, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
4 Insider stock transaction report March 17, 2026 View on SEC
8-K Current report of material events February 11, 2026 View on SEC

Annual Reports

10-K March 26, 2026
  • Successful Phase 2 clinical trial results for verekitug in both nasal polyps and asthma.
  • Pipeline expansion with a new Phase 2 trial initiated for COPD in July 2025.
View Analysis

Insider Trading

SELL 5 insiders 5 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.